Pharmaceuticals

Processa Pharmaceuticals

Processa Pharmaceuticals released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0723 (forecast USD -0.08)

Processa Pharmaceuticals released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.6225

Processa Pharmaceuticals released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2526 (forecast USD -0.22)

Processa Pharmaceuticals released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -0.5457

Processa Pharmaceuticals Reschedules Annual General Meeting to July 18, 2025

Processa terminates licensing agreement with Ocuphire and grants Intact licensing option

Processa Pharmaceuticals Inc continues to recruit patients for PCS6422 Phase 2 study

Processa Pharmaceuticals Initiates Metastatic Breast Cancer Clinical Trial and Plans PCS499 Phase III Study

Processa Pharmaceuticals Raises $7 Million Through IPO

Processa Grants Intact Exclusive Option for Phase II Gastroparesis Drug Candidate

Processa Pharmaceuticals to Present Cancer Drug Progress at ASCO Annual Meeting

Processa Pharmaceuticals released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2975 (forecast USD -0.49)

Processa Pharmaceuticals Inc Forecasting a Loss of 77 Cents per Share

Processa Pharmaceuticals released FY2024 annual earnings on March 20 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -3.8727 USD (forecast -4.05 USD)

Processa Pharmaceuticals released FY2024 Q4 earnings on March 20 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.7774 USD (forecast -0.92 USD)

Processa Pharmaceuticals released FY2024 9 Months Earnings on October 30 (EST) with actual revenue of 0 USD and EPS of -3.1475 USD

Processa Pharmaceuticals released FY2024 Q3 earnings on October 30, 2024 (EST), with actual revenue of 0 USD (forecast 0 USD) and EPS of -1.0331 USD (forecast -1 USD)

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals announces positive results from dose escalation trial in gastrointestinal cancer

Processa Pharmaceuticals released FY2023 Q4 earnings on March 29 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.7075 USD (forecast -1.6 USD)

Vision Marine Tech

SRX Health Solutions

AMC Robotics

Everbright Digital

Cementos Pacasmayo Saa 

B Riley Financial

Rezolve AI

Emerald

Venus Concept

Aldeyra Therap

Reverse Stock Split

合股

Ex Date: 2025.12.17 (EST), 1-for-25 Reverse Stock Split

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap